Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Fenaux, P; Gobbi, M; Kropf, PL; Issa, JPJ; Roboz, GJ; Mayer, J; Krauter, J; Robak, T; Kantarjian, H; Novak, J; Jedrzejczak, WW; Thomas, X; Ojeda-Uribe, M; Miyazaki, Y; Min, YH; Yeh, SP; Brandwein, J; Gercheva-Kyuchukova, L; Demeter, J; Griffiths, E; Yee, K; Döhner, K; Hao, Y; Keer, H; Azab, M; Döhner, H

Fenaux, P (通讯作者)，Univ Paris, Serv Hematol Seniors, Hop St Louis, APHP Nord,Dept DMU Hematol & Immunol, 1 Ave Claude Vellefaux, F-75475 Paris, France.

BLOOD ADVANCES, 2023; 7 (17): 5027

Abstract

This phase 3 study evaluated the efficacy and safety of the new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索